Business
Interim Results Announcement
Interim Results Announcement.
About this update from Genedrive Plc
[{"type":"text","content":"\n \n\n\n\n\n\nRNS Number : 9912B Epistem Holdings plc 28 February 2011 \n\n \n \nEpistem Holdings Plc\n \n28 February 2011\n \nEpistem Plc (LSE: EHP), the rapidly growing UK Biotechnology and Personalised Medicine company will be announcing its interim results for the six months ended 31 December 2010 on Tuesday, 29 March 2011. \n \nThe analysts' meeting will be held at the offices of Peel Hunt LLP, 111 Old Broad Street, London EC2N 1PH at 10.00 am. \n \n \n \n \n\n\n\n\nEpistem Plc\n\n\n\n\n\n\n\n\n\n\nMatthew Walls \n\n\nChief Executive Officer\n\n\n+44 (0) 161 606 7258\n\n\n\n\nJohn Rylands \n\n\nFinance Director\n\n\n+44 (0) 161 606 7244\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP \n\n\n\n\n\n\n\n\n\n\nJames Steel\n\n\n\n\n\n+44 (0) 207 418 8900\n\n\n\n\nVijay Barathan\n\n\n\n\n\n+44 (0) 207 418 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDe Facto Communications\n\n\n\n\n\n\n\n\n\n\nMike Wort / Anna Dunphy\n\n\n\n\n\n+44 (0) 20 7861 3838\n\n\n\n\n \n \n \nNotes to Editors: \n \nAbout Epistem \nEpistem is a biotechnology and Personalised Medicine company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatological applications. Epistem develops innovative therapeutics, biomarkers and diagnostics and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. \n \nEpistem operates three distinct business divisions, Contract Research Services, Novel Therapies and Personalised Medicine (biomarker and diagnostics). \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NORPGUGPPUPGGWR\n\n \n ","length":6232,"tagName":"div"}]